Compare LITE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITE | ILMN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 20.4B |
| IPO Year | N/A | 2000 |
| Metric | LITE | ILMN |
|---|---|---|
| Price | $552.87 | $116.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | ★ $483.15 | $124.24 |
| AVG Volume (30 Days) | ★ 5.5M | 2.4M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 3.27 | ★ 5.45 |
| Revenue | $2,105,200,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $62.67 | $3.50 |
| Revenue Next Year | $36.29 | $6.30 |
| P/E Ratio | $172.03 | ★ $21.43 |
| Revenue Growth | ★ 48.89 | N/A |
| 52 Week Low | $45.65 | $68.70 |
| 52 Week High | $603.83 | $155.53 |
| Indicator | LITE | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 72.27 | 30.42 |
| Support Level | $530.29 | $112.65 |
| Resistance Level | $603.83 | $119.92 |
| Average True Range (ATR) | 46.70 | 5.01 |
| MACD | 15.56 | -3.49 |
| Stochastic Oscillator | 84.18 | 10.19 |
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.